New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2014
06:11 EDTMRK, NVO, BMYFDA eases worries regarding certain diabetes medications, AP says
The federal Food and Drug Administration and its European counterpart started reviews last year of diabetes drugs which include Merck's (MRK) Januvia and Janumet, Novo Nordisk's (NVO) Victoza and Bristol-Myers Squibb's (BMY) Byetta and Bydureon, reported the Associated Press. Both U.S. and European regulators have found no evidence of a link between these drugs and pancreas problems or pancreatic cancer. Reference Link
News For MRK;NVO;BMY From The Last 14 Days
Check below for free stories on MRK;NVO;BMY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 22, 2014
12:39 EDTBMYThese five companies will benefit from increased ALS awareness, MarketWatch says
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link
August 21, 2014
13:32 EDTBMYBristol-Myers, Pfizer announce approval of Eliquis for treatment of DVT, PE
Subscribe for More Information
August 20, 2014
08:03 EDTBMYBristol-Myers Pfizer to present new Eliquis data
Subscribe for More Information
08:02 EDTBMYBristol-Myers, Celgene enter collaboration agreement for OPDIVO, ABRAXANE
Subscribe for More Information
August 18, 2014
07:57 EDTBMY, MRKCambridge Healthtech Institute to hold a summit
6th Annual Bioprocessing Summit to be held in Boston on August 18-22.
August 13, 2014
18:02 EDTMRKMerck provides statement on role of PNEUMOVAX 23 in updated ACIP recommendations
Subscribe for More Information
16:52 EDTMRKMerck confirms FDA approval of BELSOMRA
Subscribe for More Information
15:30 EDTMRKFDA approves Belsomra sleep drug
The Food and Drug Administration approved Belsomra tablets for use as needed to treat difficulty in falling and staying asleep. Belsomra is an orexin receptor antagonist and is the first approved drug of this type. Belsomra will be dispensed with an FDA-approved patient Medication Guide that provides instructions for its use and important safety information. Belsomra is a controlled substance because it can be abused or lead to dependence. Belsomra is made by Merck, Sharpe & Dohme.
August 11, 2014
11:58 EDTNVOMannKind rallies after inking licensing agreement with Sanofi
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use